Reproductive factors and hormone use and risk of adult gliomas by Felini, Martha J. et al.
Reproductive Factors and Hormone Use and Risk of Adult
Gliomas
MJ Felini, AF Olshan, JC Schroeder, SE Carozza, R Miike, T Rice, and M Wrensch
Department of Epidemiology, University of North Texas, Fort Worth, TX (MF); Department of
Epidemiology, University of North Carolina, Chapel Hill, NC (AO, JS); Department of
Epidemiology and Biostatistics, TAMHSC School of Rural Public Health, College Station, TX
(SC); Department of Neurological Surgery, University of California San Francisco, San Francisco,
CA (MW, RM, RT)
Abstract
Previous research suggests there may be a hormonal influence on glioma risk as evidenced by
lower rates in females, change in incidence rates around ages at menarche and menopause and
presence of hormone receptors in glial tumors. Using the large San Francisco Bay Area Adult
Glioma Study, we investigated whether reported reproductive factors and hormone use were
associated with gliomas overall or with histologic subtypes among female cases (n=619) and
controls (n=650). We found that reproductive factors were generally not associated with gliomas.
Weak to moderately elevated odds ratios were observed for self-reported later age at menarche
(14+ years old versus 12–13 years old: adjusted odds ratio (AOR) = 1.39, 95% confidence interval
(CI): 1.02 –1.89), particularly for non-glioblastoma histologies (AOR = 1.64, 95% CI: 1.11–2.43).
Inverse associations were observed for ever self-reported use of exogenous hormones (oral
contraceptive use: AOR = 0.72, 95% CI: 0.53–0.99; postmenopausal hormone use: AOR = 0.56,
CI: 0.37–0.84). However, cumulative hormone exposure defined multiple ways demonstrated no
clear pattern of association. The results of this study suggest that any protective effect of hormones
on gliomas may be limited to exogenous hormones, but a more detailed history of exogenous
hormone use are needed to confirm findings.
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Introduction
Hormones play a critical role during brain development in-utero;1,2 appear to work as a
neuroprotectant via estrogen-receptor independent pathways in brain degeneration,3 and
may reduce the risk of death and degree of disability in cases of traumatic brain injury.4
Whether similar hormonal pathways are involved in the etiology or progression of brain
cancers is unknown, but cell cultures and animal studies demonstrate evidence of estrogen
directly killing glioma cells5 and inhibiting the growth of gliomas,6,7 the most common and
deadly brain tumor. Plausible mechanisms by which sex hormones may play a role in
gliomagenesis have been postulated. For example, estrogen can inhibit cell cycle entry by
increasing mitogen-activated protein kinase (MAPK) levels in astrocytes and stimulating the
AKT/PIP pathway to assist in cell cycle control.8 Other plausible mechanisms include an
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estrogen-astrocyte-TGF-β1 pathway9 and melatonin-driven neuroprotection via aromatase.
10,11
Data from human studies appear to support a hormonal influence on gliomas, including
reports of consistent excess of gliomas among males, hormone receptors in glial tumors, and
changes in incidence rates around ages at menarche and menopause. However,
epidemiologic studies using reproductive and menstrual history as surrogates of hormone
exposure have been generally inconclusive due, in part, to small sample sizes, different
histology groupings among glioma classification systems, or the combining of
heterogeneous histologic subtypes.12–22 We used data from the largest population-based
case control study of adult brain tumors to date, the San Francisco Bay Area Adult Glioma
Study, to estimate the effects of reproductive factors and hormone use on gliomas among
women. The large sample size allowed a valuable opportunity for analysis by glial tumor
subtype and further exploration of cumulative female hormone using ages at menarche and
menopause and years of exogenous hormone use to more completely characterize dose-
response relationships and improve on previous studies using reproductive variables
indicative of only one point in time.
Materials and Methods
Study participants
Details of subject recruitment and participation rates for the study series 1 and 2 have been
described previously23–25 and protocols for the most recent series 3 were the same as
previously used. Briefly, cases diagnosed with histologically confirmed incident gliomas
(International Classification of Diseases for Oncology, morphology codes 9380–9481)
between August 1991 to April 1994 (Series 1), May 1997 to August 1999 (Series 2), and
November 2001 to September 2004 (Series 3) were identified using the Northern California
Rapid Case Ascertainment program. Eligible cases had pathologically confirmed glioma,
and resided in the 6 county San Francisco Bay Area (Alameda, Contra Costa, Marin, San
Mateo, San Francisco, and Santa Clara). Controls were selected from the same residential
area as cases were identified using random digit dialing and frequency matched to cases on
age (in 5 year age groups), gender, and race/ethnicity (White, Black, Hispanic, Asian, or
other).
Of the 1905 eligible cases in the parent study, full interviews were obtained for 1408 cases
(74%) and 15 completed an abbreviated questionnaire form (1%). The remaining cases were
not included because either they could not speak English (n=24), were too ill (n=1), did not
receive physician permission (n=18), did not have sufficient specimen to confirm glioma
diagnosis (n=26), were not able to be contacted (n=63), or otherwise refused (n=267). Of the
27,285 phone numbers randomly generated to contact potential controls, 18% never
answered the phone after 10 attempts and 13% were business phone numbers. For those
phone contacts, nearly 16% refused to give information to assess eligibility and 5% were
either too ill or did not understand English. Approximately 7% (n=1908) were eligible
controls and 73% (n=1396) agreed to participate and complete the interview. The other
eligibles were dropped because either they refused (n=415), did not speak English (n=14),
were not located (n=49), or otherwise could not be used (n=43). Eligible cases and controls
for this study were restricted to females 20 years and older, leaving 619 cases and 650
controls available for analysis. Among women, the participation rates (defined as number of
cases (or controls) consenting to full interview divided by number of eligible cases (or
controls)) were 79% for cases and 79% for controls.
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Reproductive, menstrual, and exogenous hormone histories were collected via in-person or
phone interview with cases (or their proxies) and controls. On average, self-reporting cases
were interviewed within 5 months and proxies within 8 months from cases’ diagnosis
(range: 3 days – 36 months). Proxy respondents were used in 37% of cases and 0.3% of
controls. Questions asked included age at first menstrual period, age menstrual periods
stopped completely, number of live births, number of pregnancies not surviving to term
(question asked only in series 1), age at each birth, oral contraceptive use (ever/never, never/
former/current) and duration (years or months), and hormone replacement therapy use (ever/
never, never/former/current) and duration (years or months). Menopausal status was
determined by whether they were still menstruating (choices included: yes; yes, but pregnant
or postpartum; yes, but infrequently, probably perimenopausal; yes, but taking menopausal
estrogen now) or were no longer menstruating (choices included no, went through natural
menopause; no, had a hysterectomy; no, other). If they reported having a hysterectomy,
further inquiry was made into type of surgery (womb removed, womb and both ovaries
removed, womb and one ovary removed, one or both ovaries removed, type unknown).
Types of surgery were evaluated independently in association with gliomas, but were
ultimately combined into a single variable (surgical menopause) due to small numbers in
most strata. Women reporting partial hysterectomies (ovaries remained) were categorized as
premenopausal if younger than 50 years of age; women reporting a partial hysterectomy at
50 years of age or older or bilateral oopherectomy were categorized as postmenopausal. In
the instance where younger women (<45 years of age) reported not having periods due to
unknown or sundry reasons (eg. thyroid disorders, polycystic ovarian syndrome), we coded
as premenopausal. For analysis of postmenopausal hormone use, we excluded those women
with indeterminate menopausal status (n=32 cases and 3 controls). Like previous studies,
cumulative hormonal exposure was calculated using combinations of age at menopause, age
at menarche, exogenous hormone use, and parity to crudely account for variability of
hormone fluctuations throughout reproductive life.26–28 Other covariates of interest
included cigarette smoking, ethnicity, highest degree earned (education), income, and age at
diagnosis.
Statistical Analysis
Category boundaries for continuous variables were informed by univariate quartile
distributions among controls but cutpoints were primarily determined by known or
suspected biological significance provided strata contained more than five persons within
each cell. Adjusted odds ratios and 95% confidence intervals were calculated for each
reproductive, menstrual, and exogenous hormone factor independently using unconditional
logistic regression models. We identified age, ethnicity, and education for potential
confounding using causal directed acyclic graphs29 and further evaluated confounding by
stratified analysis and change in the beta coefficient after removal from models (>10%
change). Initial models adjusted for ethnicity, education, and age coded using tail-restricted
quadratic splines. Menstruation years was additionally adjusted for parity. Since adding
study series to the model containing other predictors of glioma did not notably change the
odds ratio for all reproductive factors, series was not included in the final model. In addition
to analyzing both proxy and self-respondents, we restricted models to self-report females
only. Age at diagnosis or interview, menopausal status and smoking were selected a priori as
potential effect modifiers for selected reproductive factors and tested using likelihood ratio
tests.
Effect measure modification of the ever oral contraceptive use-glioma association by ever
postmenopausal hormone use was evaluated by comparing the model with only main effects
with the model inclusive of cross-product terms ever oral contraceptive use and ever
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postmenopausal hormone use (likelihood ratio test p value < 0.10). Interaction on the
additive scale was determined by comparing the observed odds ratio in the doubly exposed
(oral contraceptive and postmenopausal hormone use) to the expected OR assuming additive
risks.
Continuous variables for main effects were modeled to test for linear trend. Beta coefficients
and p value of the Wald test were used to determine if slope differed from zero. Graphical
representations using spline regressions were utilized to confirm monotonic trends. Analyses
of associations for specific histologic types (grouped as glioblastoma and non-glioblastoma)
compared each subtype to the entire control group. All analyses were conducted using SAS
9.1 software (SAS Institute, Inc., Cary, North Carolina).
Results
Baseline characteristics of the 619 cases and 650 controls were similar except that cases
were less likely than controls to have a college education (Table 1). The average age at
diagnosis was 56.3 (standard deviation = 17.1) and the average age at interview for controls
was 55.4 (standard deviation = 16.8). Proxy respondents were much more common for cases
(37%) than controls (0.3%) due to cases’ death or disability. Of the 229 proxies in this study,
most were daughters (32%) and husbands (32%). The average ages at menarche and
menopause was 12.6 (standard deviation = 1.7) and 48.8 (standard deviation = 6.3),
respectively. Approximately 62% self-reported as postmenopausal, but a lower proportion
(52%) was observed when excluding those with indeterminate menopausal status.
Postmenopausal women were older in age and less likely to report ever using oral
contraceptives (41%) compared to premenopausal women (77%), but were otherwise
similar. The majority of tumors among cases were glioblastomas (60%). Missing
information with regard to baseline characteristics was minimal and similarly distributed
between cases and controls.
Results of multivariable analyses are presented in tables separately for all women and for
self-reporting respondents only. We discuss results of self-reporting women only (indicated
by odds ratio among index respondents, ORindex) since risk estimates were generally not
altered by proxy status and self-report is assumed to be more accurate than recall by proxy.
Reproductive factors
After adjusting for age and ethnicity, gliomas were not associated with ever giving birth
(ORindex = 0.99, 95% CI: 0.73–1.34), or gravidity (ORindex = 0.88, 95% CI: 0.46–1.69,
Table 2). Categorical odds ratios for increasing age at first birth among parous women were
near unity and the slope of the continuous trend estimate for a one-year change in age at first
birth was essentially flat (β = −0.03, 95% CI: −0.03–0.03, p trend = 0.85). Parous women
with more children had higher glioma incidence than those with fewer children, with a
change in slope per child of β = 0.08 (95% CI: −0.05–0.21, p trend = 0.23).
Menstrual factors
Using 12–13 year olds as the referent group due to the large proportion of controls with ages
at menarche during this period, higher odds ratios were observed for later age at menarche
(≥14 years versus 12–13 years old: ORindex = 1.39, 95% CI: 1.02–1.89). The odds ratio for
later age at menopause (>50 years versus 45–50 years old: ORindex = 1.15, 95% CI: 0.74–
1.80, Table 2) was consistent with no effect, as was menopausal status (postmenopausal vs.
premenopausal: ORindex = 1.14, 95% CI: 0.81–1.62, data not shown). Postmenopausal
women experiencing a later age at menarche (≥ 14 years) and early onset of menopause
(<45 years old) (ORindex = 0.87, 95% CI: 0.34–2.20) demonstrated relatively comparable
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odds ratios as compared to postmenopausal women with earlier age (<11 years) and average
or later age of menopause (ORindex = 0.74, 95% CI: 0.23–2.41, data not shown), but effect
estimates were imprecise. Further examination of menstruation years adjusted for parity was
not informative.
Stratification by histologic tumor type did not alter odds ratios, with the exception of age at
menarche (table 3). An odds ratio of 1.64 (95% CI: 1.11–2.43) was calculated for the
association between non-glioblastoma cases and later age at menarche (≥14 years) as
opposed to glioblastoma cases (ORindex = 1.16, 95% CI: 0.77–1.73).
Exogenous hormone use
Odds ratios for the association between exogenous hormone use and gliomas were
consistently below 1.0 for all cases and self-reporting cases. An inverse association was
observed for ever oral contraceptive use (ORindex = 0.72, 95% CI: 0.53–0.99, Table 4).
Among ever users, there was no suggestive trend of decreasing odds ratios with longer
duration of use, except when restricted to current users of oral contraceptives (β = −0.003
(95% CI: −0.005 – −0.001), p trend = 0.02, data not shown). Likewise, postmenopausal
hormone use was inversely associated with gliomas (ORindex = 0.56, 95% CI: 0.37–0.85),
particularly among those with surgical menopause (ORindex = 0.38, 95% CI: 0.13–1.07). The
odds ratio for postmenopausal hormone use remained below 1.0 regardless of age at
menopause. There was no evidence of linear trend with increasing duration of
postmenopausal hormone use among ever users (p trend = 0.84). Among postmenopausal
women, previous oral contraceptive use did not modify the inverse association between
postmenopausal hormone use and gliomas (table 5). The combined effects of oral
contraceptives and postmenopausal hormones were close to expectations for both additive
(OR=0.38) and multiplicative (OR=0.46, p value > 0.10) models.
Exploratory analyses by smoking status and age at diagnosis did not uncover effect measure
modification.
Discussion
In this large population based case-control study, we generally found no association between
reproductive factors and gliomas. Possible exceptions include elevated odds ratios with
older age at menarche and protective effects with exogenous hormone use (oral
contraceptives and postmenopausal hormonal therapy). Previous studies exploring the
relationship between older age at menarche and gliomas found similar results as ours (risk
estimates ranged from 1.59 to 2.10).13,15,18–20 In contrast, we did not observe a difference
in risk by menopausal status nor did we find support of a trend with increasing age at
menarche as suggested in previous studies.15,20 Of the few studies stratifying by glioma
subtype, ours is the first to demonstrate that older age at menarche is stronger among non-
glioblastomas.
Our findings of an inverse association between gliomas and oral contraceptive use and
postmenopausal hormone use need to be interpreted cautiously. Given that educational level
has been inversely associated with gliomas, the protective effect we observed with use of
exogenous hormones may be due to selection bias. If controls of higher education status had
been more likely to participate, odds ratios may be overestimated since hormone use is more
common among women earning higher education degrees. Nevertheless, our findings agree
with most previous case-control studies.13,15,18,19,21,22 Only one prospective study
reported hazard ratios slightly above the null for oral contraceptive use (HR = 1.04, 95% CI:
0.72–1.50),20 but it is difficult to directly compare their results to those of our case-control
because self-reported hormone use was assessed only at baseline. Similar to other studies,
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there was generally no suggestive trend of decreasing odds ratios with increasing duration of
exogenous hormone use.15,19–22 To our knowledge, this is the first study to examine
potential interaction between oral contraceptives and postmenopausal hormone use. We
found no evidence of synergism or antagonism between postmenopausal hormone use and
previous oral contraceptive use and gliomas among self-reporting postmenopausal women.
Whether these associations are causal or artifactual are unclear since women who use
hormonal therapies may be generally healthier.30–31
Several studies have investigated the relation between parity and gliomas, but with
conflicting results. Four of six studies reported parous women were at reduced risk of
gliomas compared with nulliparous women. In the largest population based case control
study to date (N=1657 glioma cases), Lambe et al. reported a 24% reduced risk in ever
parous Swedish women compared to nulliparous women (OR = 0.76 95% CI: 0.66–0.87).12
A more recent but smaller hospital based case control study found similar, but non-
significant, results (OR = 0.85 95% CI: 0.54 – 1.35),19 whereas odds ratio for parity were
near the null in our study. These findings differ from a population-based study restricted to
rural women in the upper Midwestern States (N=341 cases) which reported an elevated odds
ratio (OR = 1.22 95% CI: 0.77–1.96) with ever giving birth and gliomas.15 Our results of no
association with increasing number of children agree with most, but not all,12,19 previous
studies.
No associations were detected for gravidity, age at first birth, or menopausal status. In
addition, there was no clear pattern of association with age at menopause, even when
excluding women with indeterminant or unknown menopausal status (that is, including only
women reporting natural menopause or bilateral oopherectomy).
Given the evidence from animal studies of the protective effect of estrogen on gliomagenesis
and survival, 32–36 the growing literature supporting the role of estrogen (and estrogen
metabolites) as a neuro-protectant, particularly in estrogen receptor independent pathways,
37–39 and observations of other female hormones known to restrict angiogenesis in vascular
tumors40 like glioblastomas, it is reasonable to expect that greater hormonal exposure would
be favorable. Findings from this study do not generally support our hypothesis that greater
cumulative exposure to hormones decreases glioma risk. Earlier, rather than later, age at
menopause was inversely associated with gliomas, albeit insignificantly. Earlier age at first
birth among parous women was near the null and greater menstruation years did not
decrease risk in this study of urban women. This is in contrast to findings of decreasing odds
ratios with increasing number of menstruation months among rural women.15 Our definition
of cumulative exposure (menstruation years) relied on varying definitions, all of which were
assessed, but all without information about menstrual regularity. Odds ratios for
menstruation years may be overestimated if cases reporting earlier age at menarche and later
age at menopause had sporadic menstrual cycles compared to controls. The inconsistency
between definitions of cumulative exposure suggests more robust measures are needed to
tease out potential differences in effect between exogenous and endogenous hormones.
Although this is one of the largest case-control studies examining reproductive factors and
hormonal use in gliomas, there were still important limitations that may affect interpretation
of our results. First, delays in interviewing cases may have resulted in a greater amount of
exposure misclassification among cases since gliomas can rapidly affect memory and mental
functioning. Rapid case ascertainment strategies used in this study likely minimized this
potential bias. In addition, non-differential misclassification may have occurred with age at
menopause since the menopausal transition makes it difficult to precisely recall age at
menopause. Excluding proxies as a strategy to avoid information bias is not optimal since
exclusion may create selection bias.41 Second, controls selected using random digit dialing
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(RDD) may have created selection bias if responders differed systematically from non-
responders.42 Since we do not know more about non-responders, it is difficult to assess the
magnitude and direction of this bias. If non-response was driven by telecommunication
advances (more cell phone use during series 3 than series 1), we might have expected the
odds ratios to differ by series, which we did not. Third, our study lacked detailed
information on the hormonal composition of exogenous hormones used and time since last
use in order to account for appropriate latency periods. Finally, reproductive factors may be
too broad to capture the ‘windows’ of relevant exposure when one hormone has more
impact than another. Exploring such a hypothesis would benefit from the additional
consideration of testosterone, for which there is currently no good surrogate. Understanding
the independent function of testosterone, estrogen, progesterone in the nervous system is
complex due to their apparent dual functions. The same hormone may create a different
response in males than females and this difference may vary from one brain region to
another 43–44 adding to the complexity of which hormone (or more likely which group of
hormones) would be largely responsible for lower incidence of gliomas in females.
Strengths of this present study were the relatively large number of histologically confirmed
glioma cases and the availability of more detailed information to detect subtle differences in
the effect of potential cumulative hormonal exposure. However, we cannot rule out the
possibility that the few notable findings were due to other explanations, such as exposure
misclassification and unknown or uncontrolled confounders including demographic or social
correlates of the reproductive experience.
This study is an important addition to existing literature regarding reproductive factors and
gliomas. We provided some of the first results comparing reproductive factors with glioma
histologic subtype. Although we observed no overall association with reproductive factors in
this study, there was a suggestion of increased risk with older age at menarche, consistent
with several previous studies. Our study provided evidence that this positive association is
stronger in non-glioblastomas. We acknowledge that non-glioblastomas are still a
heterogenous group of tumors, but these results may give insight into differences in risk
factors by glioma subtype and impress the need for larger studies (or combining existing
studies) in order to garner adequate power for subtype-specific analysis. Furthermore, this
study used cumulative exposure as the important next step toward moving beyond assessing
reproductive events that are relevant to one point in time. Cumulative exposure, as defined
multiple ways in our study, does not appear to be an important in glioma risk, contrary to an
observed protective effect among rural women. Given the consistent protective effect with
oral contraceptive and postmenopausal hormone use across previous studies, this study was
the first to assess whether a potential cumulative or synergistic effect may be relegated to
exogenous hormone use only. Future epidemiologic studies could benefit from a more
detailed account of exogenous hormone, but without a greater understanding of hormone
function in the nervous system interpretation will remain limited. Potentially as informative
would be developing a grouping classification system of reproductive factors that could
serve as meaningful indices of hormone-specific aggregates to more closely resemble their
physiologic function in the body. Future epidemiologic studies could benefit from a more
detailed account of exogenous hormone use to confirm findings, but without a greater
understanding of hormone function in the nervous system in relation to mechanisms of
gliomagenesis interpretation will remain limited. Potentially as informative would be
developing a grouping classification system of reproductive factors that could serve as
meaningful indices of hormone-specific aggregates (which more closely resembles their
physiologic function in the body).
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Table 1
Selected characteristics of glioma cases and controls among female participants in the San Francisco Adult
Glioma Study, 1991–2004
Female participants
Case (n=619) Control (n=650)
n (%) n (%)
Age at interview (yrs)
    20–44 173 (28) 192 (30)
    45–54 95 (15) 118 (18)
    55–64 121 (20) 117 (18)
    65+ 230 (37) 223 (34)
    mean (sd) 56.3 (17.0) 55.4 (16.8)
Ethnicity
    White 494 (80) 525 (81)
    Black 30 (5) 30 (5)
    Asian 32 (5) 36 (6)
    Hispanic/Mexican 44 (7) 40 (6)
    Other 19 (3) 19 (3)
Smoking 100 cigarettes
    Never 325 (53) 332 (51)
    Past 225 (36) 234 (36)
    Current 66 (11) 83 (13)
    Missing 3 1
Education
    High school or less 301 (49) 259 (40)
    College 232 (37) 305 (47)
    Graduate school/Professional 85 (14) 86 (13)
    Missing 1 0
Income
    <30,000 153 (25) 194 (30)
    30,000–70,000 221 (36) 222 (34)
    70,000+ 210 (34) 219 (34)
    Missing 35 (6) 15 (2)
Marital Status
    Single 75 (12) 91 (14)
    Married/spouse 355 (57) 299 (46)
    Separated/divorced 85 (14) 145 (22)
    Widowed 104 (17) 114 (18)
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Female participants
Case (n=619) Control (n=650)





Numbers do not always total to 100% due to rounding
*
other=ependymoma, subependymoma, juvenile pilocytic, astrocytoma- not classified, medulloblastoma, gangliogliomas, and not specified
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Table 5
Adjusted OR (95% CI) for interaction between oral contraceptive use and postmenopausal hormone use and






use among self-reporting women
Ever postmenopausal hormone use
among self-reporting women
Case/control OR† (95% CI) Case/control OR† (95% CI)
Never 38/69 1.00 (ref) 37/108 0.55 (0.30–0.98)




use among all women
Ever postmenopausal hormone use
among all women
Case/control OR† (95% CI) Case/control OR† (95% CI)
Never 102/70 1.00 (ref) 84/108 0.57 (0.37–0.88)
Ever 45/45 0.60 (0.33–1.10) 61/106 0.36 (0.20–0.64)
†
adjusted for frequency matched factors age (restricted quadratic splines), ethnicity and education
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